Amneal Pharmaceuticals (AMRX) Revenue & Revenue Breakdown

Overview ForecastOwnership Financials Chart Transcripts

Amneal Pharmaceuticals Revenue Highlights

Latest Revenue (Y)

$2.39B

Latest Revenue (Q)

$702.47M

Main Segment (Y)

Generics Segment

Main Geography (Y)

Generics Segment

Amneal Pharmaceuticals Revenue by Period

Amneal Pharmaceuticals Revenue by Year

Date	Revenue	Change
2023-12-31	$2.39B	8.20%
2022-12-31	$2.21B	5.67%
2021-12-31	$2.09B	5.08%
2020-12-31	$1.99B	22.51%
2019-12-31	$1.63B	-2.20%
2018-12-31	$1.66B	60.88%
2017-12-31	$1.03B	1.52%
2016-12-31	$1.02B	-

Amneal Pharmaceuticals generated $2.39B in revenue during NA 2023, up 8.20% compared to the previous quarter, and up 143.93% compared to the same period a year ago.

Amneal Pharmaceuticals Revenue by Quarter

Date	Revenue	Change
2024-09-30	$702.47M	0.10%
2024-06-30	$701.78M	6.46%
2024-03-31	$659.19M	6.84%
2023-12-31	$616.98M	-0.49%
2023-09-30	$620.04M	3.50%
2023-06-30	$599.05M	7.44%
2023-03-31	$557.54M	-8.56%
2022-12-31	$609.76M	11.77%
2022-09-30	$545.56M	-2.47%
2022-06-30	$559.36M	12.40%
2022-03-31	$497.63M	-7.31%
2021-12-31	$536.90M	1.57%
2021-09-30	$528.59M	-1.21%
2021-06-30	$535.08M	8.51%
2021-03-31	$493.11M	-3.32%
2020-12-31	$510.03M	-1.78%
2020-09-30	$519.29M	11.76%
2020-06-30	$464.66M	-6.79%
2020-03-31	$498.53M	25.47%
2019-12-31	$397.33M	5.03%
2019-09-30	$378.28M	-6.51%
2019-06-30	$404.64M	-9.30%
2019-03-31	$446.12M	-10.33%
2018-12-31	$497.53M	4.42%
2018-09-30	$476.49M	15.15%
2018-06-30	$413.79M	50.36%
2018-03-31	$275.19M	-6.20%
2017-12-31	$293.37M	15.17%
2017-09-30	$254.73M	-1.98%
2017-06-30	$259.87M	15.15%
2017-03-31	$225.68M	-24.41%
2016-12-31	$298.58M	-

Amneal Pharmaceuticals generated $702.47M in revenue during Q3 2024, up 0.10% compared to the previous quarter, and up 117.26% compared to the same period a year ago.

Amneal Pharmaceuticals Revenue Breakdown

Amneal Pharmaceuticals Revenue Breakdown by Product

Annual Revenue by Product

Product/Service	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
Specialty Segment	$390.46M	$317.53M	-	-	-
Generics Segment	$1.47B	$1.43B	$1.37B	$1.34B	$1.29B
Amneal Specialty Pharma Segment	-	$374.12M	$378.32M	$355.57M	-
Av K A R E Segment	-	$406.11M	-	-	-
Av Kare	-	-	$349.01M	$293.75M	-

Amneal Pharmaceuticals's latest annual revenue breakdown by segment (product or service), as of Dec 23: Generics Segment (79.03%), and Specialty Segment (20.97%).

Quarterly Revenue by Product

Product/Service	Sep 24	Mar 24	Dec 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19
Generics Segment	$427.35M	$391.29M	$753.89M	$373.70M	$343.81M	$399.17M	$350.27M	$364.89M	$317.75M	$346.27M	$347.13M	$360.44M	$312.51M	$342.14M	$341.92M	$306.56M	$985.00K	$300.28M	-	-
Amneal Specialty Pharma Segment	$115.64M	$105.23M	$96.99M	$91.68M	$102.55M	$89.48M	$97.00M	$85.09M	$101.01M	$92.75M	$95.93M	$85.47M	$87.87M	$94.26M	$97.05M	-	-	-	-	-
Av K A R E Segment	-	-	-	$128.35M	$122.06M	$108.04M	$105.81M	$97.46M	$94.80M	$88.72M	$86.00M	$84.67M	$89.51M	$63.85M	$57.97M	-	-	-	-	-
Specialty Segment	-	-	-	-	-	-	-	-	-	-	-	$88.64M	$87.98M	-	-	-	-	-	-	-
Rytary Family	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$33.71M	$33.00M
Oxymorphone	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$17.14M	-
Levothyroxine Sodium	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$39.77M	$46.46M
Epinephrine Auto Injector Family Generic Adrenaclick	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$22.69M	-
Diclofenac Sodium Gel	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$19.26M	$25.01M
Yuvafem-Estradiol	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$14.02M
Epinephrine Auto-Injector Family (Generic Adrenaclick)	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$15.96M

Amneal Pharmaceuticals's latest quarterly revenue breakdown by segment (product or service), as of Sep 24: Generics Segment (78.70%), and Amneal Specialty Pharma Segment (21.30%).

Amneal Pharmaceuticals Revenue Breakdown by Country

Annual Revenue by Country

Country	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
Generics Segment	$1.47B	$41.09M	$35.97M	$37.39M	$1.29B
Specialty Segment	$390.46M	$374.12M	$378.32M	$355.57M	$317.53M

Amneal Pharmaceuticals's latest annual revenue breakdown by geography, as of Dec 23: Generics Segment (79.03%), and Specialty Segment (20.97%).

Quarterly Revenue by Country

Country	Sep 24	Mar 24	Dec 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19
Generics Segment	$427.35M	$391.29M	$1.45B	$11.14M	$12.81M	$14.58M	$8.72M	$12.12M	$5.67M	$9.09M	$8.23M	$10.46M	$8.18M	$9.19M	$10.88M	$7.24M	$985.00K	$300.28M	$291.02M	$335.06M
Specialty Segment	$115.64M	$105.23M	$201.78M	$96.99M	$91.68M	$102.55M	$89.48M	$97.00M	$85.09M	$101.01M	$92.75M	$88.64M	$95.93M	$85.47M	$87.87M	$94.26M	$87.98M	-	-	-

Amneal Pharmaceuticals's latest quarterly revenue breakdown by geography, as of Sep 24: Generics Segment (78.70%), and Specialty Segment (21.30%).

Amneal Pharmaceuticals Peer Comparison by Revenue

Ticker	Company	Last Year Revenue	Last Quarter Revenue
AMRX	Amneal Pharmaceuticals	$2.39B	$702.47M
NBIX	Neurocrine Biosciences	$1.89B	$622.10M
ALKS	Alkermes	$1.66B	$378.14M
PAHC	Phibro Animal Health	$977.89M	$273.16M
AMPH	Amphastar Pharmaceuticals	$593.24M	$188.82M
COLL	Collegium Pharmaceutical	$566.77M	$159.30M
ANIP	ANI Pharmaceuticals	$486.82M	$148.33M
ITCI	Intra-Cellular Therapies	$462.18M	$175.38M
IRWD	Ironwood Pharmaceuticals	$442.74M	$91.59M
PROC	Procaps Group	$409.92M	$118.41M
DVAX	Dynavax	$232.28M	$79.34M
EOLS	Evolus	$199.72M	$60.16M
ASRT	Assertio	$152.07M	$29.20M
LFCR	Lifecore Biomedical	$128.26M	$24.70M

AMRX Revenue FAQ

What is Amneal Pharmaceuticals’s yearly revenue?

Amneal Pharmaceuticals's yearly revenue for 2023 was $2.39B, representing an increase of 8.20% compared to 2022. The company's yearly revenue for 2022 was $2.21B, representing an increase of 5.67% compared to 2021. AMRX's yearly revenue for 2021 was $2.09B, representing an increase of 5.08% compared to 2020.

What is Amneal Pharmaceuticals’s quarterly revenue?

Amneal Pharmaceuticals's quarterly revenue for Q3 2024 was $702.47M, a 0.10% increase from the previous quarter (Q2 2024), and a 13.29% increase year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $701.78M, a 6.46% increase from the previous quarter (Q1 2024), and a 17.15% increase year-over-year (Q2 2023). AMRX's quarterly revenue for Q1 2024 was $659.19M, a 6.84% increase from the previous quarter (Q4 2023), and a 18.23% increase year-over-year (Q1 2023).

What is Amneal Pharmaceuticals’s revenue growth rate?

Amneal Pharmaceuticals's revenue growth rate for the last 3 years (2021-2023) was 14.33%, and for the last 5 years (2019-2023) was 47.17%.

What are Amneal Pharmaceuticals’s revenue streams?

Amneal Pharmaceuticals's revenue streams in c 23 are Specialty Segment, and Generics Segment. Specialty Segment generated $390.46M in revenue, accounting 20.97% of the company's total revenue, up 22.97% year-over-year. Generics Segment generated $1.47B in revenue, accounting 79.03% of the company's total revenue, up 2.75% year-over-year.

What is Amneal Pharmaceuticals’s main source of revenue?

For the fiscal year ending Dec 23, the largest source of revenue of Amneal Pharmaceuticals was Generics Segment. This segment made a revenue of $1.47B, representing 79.03% of the company's total revenue.